Coinfection of pneumocystis jiroveci pneumonia and pulmonary aspergillosis in a non-HIV-infected patient

Journal of Microbiology, Immunology and Infection

Volumn 51, Issue 6, 2018, Pages 860-861

  Lee, Po Hsin ^a   Fu, Pin Kuei ^a,b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; MICAFUNGIN; MYCOPHENOLATE MOFETIL; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; FUNGUS ANTIGEN;

ADULT; ANTIBIOTIC THERAPY; ANTIFUNGAL THERAPY; CASE REPORT; CLINICAL ARTICLE; COUGHING; CRACKLE; DYSPNEA; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; LETTER; LUNG ASPERGILLOSIS; LUNG LAVAGE; MIXED INFECTION; PNEUMOCYSTIS PNEUMONIA; THORAX RADIOGRAPHY; X-RAY COMPUTED TOMOGRAPHY; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; COMPLICATION; DIAGNOSTIC IMAGING; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LUNG; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; BRONCHOALVEOLAR LAVAGE FLUID; COINFECTION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY TRANSPLANTATION; LUNG; PNEUMONIA, PNEUMOCYSTIS; PULMONARY ASPERGILLOSIS; TREATMENT OUTCOME;

EID: 85057420850     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2018.11.001     Document Type: Letter

References (5)

1. Kung, H.C., Huang, P.Y., Chen, W.T., Ko, B.S., Chen, Y.C., Chang, S.C., et al., Infectious Diseases Society of Taiwan. Medical foundation in Memory of Dr. Deh-Lin Cheng; foundation of Professor Wei-Chuan Hsieh for infectious diseases research and education; CY Lee's research foundation for pediatric infectious diseases and vaccines. 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan. J Microbiol Immunol Infect 51 (2018), 1–17.
2. Jung, J., Kim, M.Y., Chong, Y.P., Lee, S.O., Choi, S.H., Kim, Y.S., et al. Clinical characteristics, radiologic findings, risk factors and outcomes of serum galactomannan-negative invasive pulmonary aspergillosis. J Microbiol Immunol Infect, 2017 Jun 29 pii: S1684-1182(17)30102-0. doi: 10.1016/j.jmii.2017.05.007. [Epub ahead of print].
3. Li, M.C., Lee, N.Y., Lee, C.C., Lee, H.C., Chang, C.M., Ko, W.C., Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 47 (2014), 42–47.
4. Goto, N., Futamura, K., Okada, M., Yamamoto, T., Tsujita, M., Hiramitsu, T., et al. Management of pneumocystis jirovecii pneumonia in kidney transplantation to prevent further outbreak. Clin Med Insights Circulatory, Respir Pulm Med 9 (2015 15), 81–90.
5. Markantonatou, A.M., Ioakimidou, A., Arvaniti, K., Manou, E., Papadopoulos, V., Kiriklidou, P., et al. Pulmonary co-infections by pneumocystis jirovecii and aspergillus fumigatus in non-HIV patients: a report of two cases and literature review. Mycoses 60 (2017), 626–633.